X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

TGTX

Closed

Tg Therapeutics Inc

35.4
-0.6 (-1.67%)
Last Update: 01 Jul 2025 23:05:00
Yesterday: 35.99
Day's Range: 35.1 - 36.9099
Send
When Written:
 
21.93
TG Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative treatments for B-cell malignancies and autoimmune diseases. The company's lead product candidate is ublituximab, a novel monoclonal antibody that targets a specific protein on the surface of B-cells, which are the immune cells responsible for producing antibodies. Ublituximab is being developed for the treatment of various B-cell malignancies, including chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), and multiple myeloma. The company also has a pipeline of other product candidates, including umbralisib, a PI3K delta inhibitor, and TG-1701, a BTK inhibitor, both of which are being developed for the treatment of B-cell malignancies and autoimmune diseases. TG Therapeutics was founded in 1993 and is headquartered in New York City.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X